Patent application number | Description | Published |
20090202500 | Pharmaceuticals That Promote Functional Regeneration of Damaged Tissues - The present inventors revealed the following for the first time in the world:
| 08-13-2009 |
20110091928 | Agent for Recruitment of Bone-Marrow-Derived Pluripotent Stem Cell Into Peripheral Circulation - The present invention for the first time demonstrated that: | 04-21-2011 |
20110097309 | Pharmaceutical Agent for Promoting the Functional Regeneration of Damaged Tissue - The present inventors assessed the possibility that bone marrow-derived cells are mobilized to the grafted skin from nonskin tissues and contribute to skin tissue regeneration during the engraftment of grafted skin on biological tissues. As a result, the present inventors for the first time in the world demonstrated that: | 04-28-2011 |
20110104803 | Method for Collecting Functional Cells In Vivo with High Efficiency - Biologically low invasive vessels are filled with biological factors that have the activity of mobilizing specific functional cells in the body. The vessels are indwelled in the body. After specific functional cells are mobilized into the vessels, the vessels are removed from the body to collect functional cell populations mobilized to the vessels. Alternatively, the cells are directly collected from the vessels indwelled in the body. | 05-05-2011 |
20120251510 | AGENTS FOR PROMOTING TISSUE REGENERATION BY RECRUITING BONE MARROW MESENCHYMAL STEM CELLS AND/OR PLURIPOTENT STEM CELLS INTO BLOOD - It was revealed that the intravenous administration of HMGB-1 and S100A8 promoted the healing of skin ulcer by recruiting bone marrow-derived cells to the site of skin ulcer. Furthermore, when HMGB-1 was intravenously administered to cerebral infarction model mice after creation of cerebral infarction, bone marrow-derived cells expressing nerve cell markers were detected in their brain. A marked cerebral infarct-reducing effect was observed in mice intravenously administered with HMGB-1 as compared to the control. The post-cerebral infarction survival rate was increased in the intravenous HMGB-1 administration group. The involvement of bone marrow pluripotent stem cells in the process of bone fracture healing was assessed using mice, and the result demonstrated that bone marrow-derived cells distant from the damaged site migrated to the bone fracture site to repair the damaged tissue. | 10-04-2012 |
20140206619 | PEPTIDE FOR INDUCING REGENERATION OF TISSUE AND USE THEREOF - (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFRα-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. | 07-24-2014 |
20150273017 | Novel Method for Treating Cardiac Infarction Using HMGB1 Fragment - A fragment peptide having a proper length composed of a part of an HMGB1 protein was synthesized and the peptide was confirmed to exhibit therapeutic effects on myocardial infarction. | 10-01-2015 |
20150274792 | Novel Method for Treating Spinal Cord Injury Using HMGB1 Fragment - Fragment peptides having a proper length, which consists of a portion of the HMGB1 protein were synthesized, and the peptides were confirmed to show therapeutic effects on injury of the spinal cord. | 10-01-2015 |